Mitsubishi Gas Chemical Company (4182) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
3 Jul, 2026Management overview and strategic direction
Pursuing transformation into an excellent company with uniqueness and presence, focusing on innovation and business portfolio resilience.
Medium-term plan 'Grow UP 2026' targets strengthening business resiliency and promoting sustainability management.
Vision for 2030 centers on leveraging chemistry for societal value and sustainable growth.
Progress on medium-term management plan
Significant investments in ICT businesses, including capacity expansion in Thailand for IC packaging materials and ongoing EL chemicals projects.
Delays in reaping returns from some investments, especially EL chemicals, with impairment losses impacting FY2025 results.
Business structure reforms include discontinuing unprofitable projects (MXDA in Europe, PC production at Kashima) and asset sales, yielding ¥15 billion in FY2025 earnings improvement.
Financial performance and targets
FY2025 saw a net loss due to impairment losses, but electronic materials performed well.
FY2026 targets: net sales ¥850 billion, operating profit ¥85 billion, ROE 9%+, ROIC 8%+.
Specialty Chemicals expected to drive profit growth, with Green Energy & Chemicals also improving.
Latest events from Mitsubishi Gas Chemical Company
- Strong 1Q growth from methanol and electronics, but profits to ease in later quarters.4182
Q1 2027 - FY2026 is set for strong profit recovery after FY2025's net loss and impairment charges.4182
Q4 2026 - Operating profit more than doubled on strong specialty chemicals demand and yen depreciation.4182
Q1 2025 - Operating profit surged 52.7% year-over-year, driven by Specialty Chemicals growth.4182
Q2 2025 - Operating profit rose 17.2% despite lower sales, driven by Specialty Chemicals and yen effects.4182
Q3 2025 - Operating profit up 7.4% despite 4.9% sales drop; FY2025 outlook cautious.4182
Q4 2025 - Profits fell on weak chemical markets and FX volatility, but sales forecast was raised.4182
Q1 2026 - Impairment loss and weak markets drive lower profits and a revised net loss outlook for FY2025.4182
Q2 2026 - Profits fell on lower prices and impairments, but dividend forecast raised to ¥100 per share.4182
Q3 2026